Telomerase activity and telomere length in women with breast cancer or without malignancy: A systematic review and meta-analysis.

AIM: We performed a systematic review and meta-analysis to assess whether telomerase activity and telomere length are associated with breast cancer. METHODS: PubMed, Web of Science, Embase, LILACS, Scielo, Embase, and CNKI databases were searched to obtain relevant articles published through May 10, 2023, following PRISMA guidelines and a registered PROSPERO protocol (CRD42022335402). We included observational studies reporting telomerase activity or telomere length in patients with breast cancer compared with women with benign lesions or normal tissue (control women). The Newcastle-Ottawa Scale was used to evaluate the quality of studies. Data were expressed as odds ratios (OR) and 95 % confidence intervals (CI). Random effects and inverse variance methods were used to meta-analyze associations. The I2 test was used to assess heterogeneity. RESULTS: The meta-analysis of telomerase shows significantly greater activity in patients with breast cancer than in those without malignancies (OR = 23.46, 95 % CI 14.07-39.11, p < 0.00001, I2 = 72 %). There were non-significant differences in relative telomere length (OR = 1.16, 95 % CI = 0.90-1.49, p = 0.26, I2 = 86 %) and leukocyte telomere length (OR = 2.32, 95 % CI = 0.89-6.08, p = 0.09, I2 = 98 %) between women with and without breast cancer. In subgroup analyses by world regions of studies, both telomerase activity and telomere length displayed the same trends as in their respective meta-analyses. In sensitivity analyses, variables showed their respective same trends. CONCLUSION: Telomerase activity is higher in patients with breast cancer than in women without malignancies. There were no significant differences in either relative telomere length or leukocyte telomere length in women with and without breast cancer. PROSPERO protocol CRD42022335402.

Colposcopy in the Primary Health Care: A Scoping Review.

AIM: Low- and middle-income countries represent nearly 85% of all cervical cancer cases worldwide; thereby, it is extremely important to identify methods to improve the screening process. Therefore, this study aimed to summarize the primary characteristics of studies on accessibility, coverage, patient preferences, and factors associated with patient satisfaction or acceptance of colposcopy in primary healthcare. METHODS: A search strategy, based on MeSH, Emtree, and free terms, was run through 5 databases (PubMed, Scopus, Embase, Ovid/Medline, and Web of Science). EndNote 20.1 © and Rayyan QCRI © were used for screening. A preset datasheet was used for data extraction. RESULTS: The systematic search retrieved 1127 references, and after removing duplicates, screening the titles and abstracts, and reviewing the full text, 7 studies were included. The interrater reliability was 77.73% (kappa statistic = 0.1842). Most studies estimated the proportion of women that sought for colposcopy after a previous screening test for human papilloma virus. One study identifies barriers to colposcopy examination in women at risk of developing cervical cancer. Three studies assessed the decentralization of colposcopy from a tertiary healthcare center to a primary care center. Pap smear was the most common first-line screening test, followed by liquid-based cytology sample and visual inspection with acetic acid. CONCLUSION: Only a few countries have investigated the use of colposcopy in primary care. Thus, barriers and the care structure for this implementation to be successful in reducing cervical cancer incidence and mortality should be identified.

Endometrial telomerase activity in women with either endometrial cancer or hyperplasia: A systematic review and meta-analysis.

AIM: We performed a systematic review and meta-analysis to assess whether endometrial telomerase activity is associated with endometrial cancer or hyperplasia. METHODS: PubMed, Web of Science, Embase, Scielo, LILAC, and CNKI databases were searched to obtain relevant literature for articles published through June 2022, following PRISMA guidelines and a registered PROSPERO protocol. We included observational studies reporting endometrial telomerase activity in patients with either endometrial cancer or hyperplasia compared with benign endometrial tissue (control women). The Newcastle-Ottawa Scale was used to evaluate the quality of studies. Data were expressed as the odds ratios (OR) and 95 % confidence intervals (CI). Random effects and inverse variance methods were used to meta-analyze associations. The I2 test was used to assess heterogeneity. RESULTS: There were significant associations between endometrial telomerase activity and either endometrial cancer (20 studies, OR = 10.65, 95 % CI 6.39, 17.75, p = 0.00001, I2 = 21 %) or endometrial hyperplasia (nine studies, OR = 3.62, 95 % CI 1.61, 8.13, p = 0.002, I2 = 36 %) compared to women without endometrial cancer and hyperplasia. There was not a significant difference in telomerase activity in women with endometrial cancer compared to those with endometrial hyperplasia (seven studies, OR = 1.03; 95 % CI 0.31, 3.37, p = 0.96, I2 = 49 %). In subgroup analyses, there were no significant differences in telomerase activity in patients with endometrial cancer by type of observational studies and by countries of the studies. CONCLUSION: Endometrial telomerase activity is higher in women with either endometrial cancer or endometrial hyperplasia compared to control women without those lesions.

Systemic Immune-Inflammation Index and Mortality in Testicular Cancer: A Systematic Review and Meta-Analysis.

The systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with overall survival (OS) and progression-free survival (PFS) in testicular cancer. We searched observational studies in five databases. The quantitative synthesis was performed using a random-effects model. The risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). The only measure of the effect was the hazard ratio (HR). A sensitivity analysis was performed according to the risk of bias in the studies. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR = 3.28; 95% CI 1.3-8.9; p < 0.001; I2 = 78) and PFS (HR = 3.9; 95% CI 2.53-6.02; p < 0.001; I2 = 0). No indication of small study effects was found in the association between SIII values and OS (p = 0.5301). High SIII values were associated with worse OS and PFS. However, further primary studies are suggested to enhance the effect of this marker in different outcomes of testicular cancer patients.

Lymphocyte-to-Monocyte Ratio and Clinical Outcomes in Cholangiocarcinoma: A Systematic Review and Meta-Analysis.

Lymphocyte-to-Monocyte ratio (LMR) has shown an association with survival outcomes in several oncological diseases. This study aimed to evaluate the association between LMR and clinical outcomes for cholangiocarcinoma patients. A systematic review and meta-analysis were performed to assess the association between LMR values and overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS) and time to recurrence (TTR) in cholangiocarcinoma patients. We used Hazard ratio (HR) and their 95% confidence interval (CI) as a measure of effect for the random effect model meta-analysis. The Newcastle-Ottawa Scale was used for quality assessment. The Egger test and funnel plot were developed for approaching publication bias. A total of 19 studies were included in this study (n = 3860). The meta-analysis showed that cholangiocarcinoma patients with low values of LMR were associated with worse OS (HR: 0.82; 95% CI: 0.71-0.96; I2 = 86%) and worse TTR (HR: 0.71; 95% CI: 0.58-0.86; I2 = 0%). DFS and RFS also were evaluated; however, they did not show statistically significant associations. Low LMR values were associated with a worse OS and TTR.

Ethic Policy Forum: Inclusión de minorías étnicas latinoamericanas en los ensayos clínicos

Objetivo: Analizar los aspectos normativos y éticos relacionados a la inclusión de las minorías étnicas en los ensayos clínicos en Latinoamérica y el Caribe. Material y Métodos : Se presentan resultados del análisis ético y normativo realizado por el grupo de investigadores en bioética, del Ethic Policy Forum; foro de análisis, discusión y formulación de propuestas en políticas y normativas relacionadas con aspectos de ética en investigación en los países de Latinoamérica y el Caribe, constituido por el Instituto de Evaluación de Tecnologías en Salud e Investigación del Seguro Social de Salud del Perú, la Universidad Católica Santa María de Arequipa, Perú y la Red Internacional de Salud Colectiva y salud Intercultural de la Universidad Autónoma del Estado de México. Resultados: Se evidencia que las minorías étnicas no están adecuadamente representadas en los ensayos clínicos en Latinoamérica y el Caribe y la normativa al respecto no está estandarizada, o no existe en todos los países de la Región. Los ensayos con minorías étnicas, pueden tener beneficios, pero también potenciales riesgos y conflictos éticos, que requieren una adecuada evaluación de las vulnerabilidades, acompañamiento efectivo en el consentimiento informado y proceso de investigación, por Comités de ética de investigación capacitados salud intercultural y en ética de la investigación con pueblos indígenas y afrodescendientes. Conclusión : Los ensayos clínicos deben incluir a minorías étnicas, con potencial beneficio de los productos de investigación. La investigación debe desarrollarse bajo principios éticos y normativas que protejan a estas minorías.

Objetive: To analyze the normative and ethical aspects related to the inclusion of ethnic minorities in clinical trials in Latin America and the Caribbean. Material and Methods : The results of the ethical and normative analysis carried out by the group of researchers in bioethics of the Ethic Policy Forum are presented; forum for analysis, discussion and formulation of proposals in policies and regulations related to aspects of ethics in research in the countries of Latin America and the Caribbean, constituted by the "Instituto de Evaluación de Tecnologías en Salud e Investigación" from Peru, the Universidad Católica Santa María de Arequipa, Peru and the International Network of Collective Health and Intercultural Health of the "Universidad Autónoma del Estado de México". Results : It is evident that ethnic minorities are not adequately represented in clinical trials in Latin America and the Caribbean and the regulations in this regard are not standardized, or do not exist in all the countries of the Region. Trials with ethnic minorities can have benefits but also potential risks and ethical conflicts, which require an adequate assessment of vulnerabilities, effective support in informed consent and the research process, by Research Ethics Committees trained in intercultural health and ethics of research with indigenous peoples and Afro-descendants. Conclusion : Clinical trials should include ethnic minorities, with potential benefit from research products. Research must be developed under ethical and regulatory principles that protect these minorities.

Factores asociados al resultado citológico positivo en pruebas de Papanicolau en mujeres atendidas en la Liga peruana de lucha contra el cáncer / Factors associated with a positive cytological result in Papanicolau tests in women attended In the Liga Peruana de Lucha contra el Cancer

Objetivo: Evaluar los factores asociados a un resultado de citología cervical positiva en la prueba de Papanicolau en una muestra de mujeres peruanas en Lima, Perú - 2013. Material y métodos: Se realizó un estudio transversal analítico que incluyó a mujeres con edades entre 21 a 64 años y empleó la prueba de Papanicolaou para evaluar la citología cervical. Se incluyó factores sociodemográficos y antecedentes de la mujer obtenidos de la historia clínica de las pacientes. Se realizaron modelos lineales generalizados de familia Poisson con varianzas robustas para evaluar los factores asociados a la citología positiva. La medida de asociación reportada fue la razón de prevalencia (RP) con sus respectivos intervalos de confianza al 95% (IC95%). Resultados: Se incluyeron a 11110 mujeres en el análisis con una edad media de 41,5±10,9 años y la prevalencia de un resultado positivo en la prueba de Papanicolau fue de 2,8%. En el modelo ajustado, se halló que tener entre 21 a 30 años (RPa=1,97;IC95%:1,30-3,00), 31 a 40 años (RPa=2,56;IC95%:1,76-3,72) y 41 a 50 años (RPa=2,16;IC95%:1,47-3,17), ser soltera (RPa=1,41;IC95%:1,10-1,83), viuda o divorciada (RPa=1,90;IC95%:1,27-2,87), haber tenido inicio de vida sexual antes de los 16 años (RPa=1,30;IC95%:1,01-1,68) o entre los 16 a 19 años (RPa=1,69;IC95%:1,22-2,36) se asoció a una mayor probabilidad de presentar un resultado de citología cervical positivo. Conclusiones: El cáncer de cuello uterino representa un problema de salud pública en Perú, por lo que identificar sus factores asociados es útil para mejorar las estrategias de tamizaje, priorizando grupos de mayor riesgo.

Objetive:To evaluate the factors associated with a positive cervical cytology result in the Pap smear test in a sample of Peruvian women from Lima, Peru - 2013. : We conducted an analytical cross-sectional Material and Methodsstudy including women from 21 to 64 years and we used the Pap smear test to evaluate cervical cytology. We included sociodemographic and medical history variables obtained from medical records of the patients. We elaborated generalized linear models from Poisson family with robust variances to evaluate the factors associated with positive cytology. The association measure reported was the prevalence ratio (PR) with their respective 95% confidence intervals (95%CI). We analyzed 11110 women with a mean age of 41.5 ± 10.9 Results: years and a prevalence of a positive Pap smear test of 2.8%. In the adjusted model, we found that women between 21 and 30 years old (aPR=1.97; 95%CI:1.30-3.00), 31 to 40 years (aPR=2.56; 95%CI:1.76 -3.72) and 41 to 50 years (aPR=2.16; 95%CI:1.47-3.17), single (aPR=1.41; 95%CI:1.10-1.83), widowed or divorced (aPR=1.90; 95%CI:1.27-2.87), with a sexual life onset before 16 years (aPR=1.30; 95%CI:1.01- 1.68) or between 16 and 19 years (aPR=1.69; 95%CI:1.22-2.36) had a greater prevalence of a positive cervical cytology result. Cervical cancer is a public health problem in Peru, then, identifying the factors associated will allow us to Conclusions:improve screening strategies and prioritize groups at higher risk.

Prognostic value of apolipoproteins in COVID-19 patients: A systematic review and meta-analysis.

INTRODUCTION: Apolipoproteins are predictive biomarkers for cardiovascular, neoplasms and cerebrovascular diseases and are postulated as prognostic biomarkers in infectious diseases, as COVID-19. Thus, we assessed the prognosis value of apolipoproteins for COVID-19 severity and mortality. METHODS: We conducted a systematic review and meta-analysis using observational studies that reported the association between apolipoproteins and severity or mortality in COVID-19 patients. Newcastle-Ottawa was used for the quality assessment of included studies. Effects measurements were shown as odds ratios (ORs) with 95% confidence intervals (CIs), and Egger-test was developed for assessing the risk of bias publication. RESULTS: We analyzed 12 cohort studies (n = 3580). Patients with low ApoliproteinA1 (ApoA1) (OR 0.35; 95%CI 0.24 to 0.49; P < 0.001) and ApoliproteinB (ApoB) (OR = 0.78; 95%CI 0.69 to 0.87; P < 0.001) values had a higher risk of developing severe disease. ApoB/ApoA1 ratio showed no statistically significant association with higher odds of severity. Low ApoA1 levels were associated with higher odds of all-cause mortality (OR = 0.34; 95%CI 0.20 to 0.57; P < 0.001). ApoB values showed no statistically significant association with a high risk of all-cause mortality. CONCLUSION: We suggest that adequate levels of ApoA1 and ApoB can be a protective factor for severity in COVID-19, and ApoB/ApoA1 ratio did not show predictive utility for severity.

Una mezcla láctea fortificada con hierro y zinc mejora los niveles de hemoglobina en niños de 2 a 10 años en una comunidad andina en Perú: Ensayo controlado aleatorizado, doble ciego / A dairy mixture fortified with iron and zinc improves hemoglobin levels in children aged 2 to 10 years in an andean community in Peru: Randomized, double-blind controlled trial

Introducción: Investigaciones anteriores coinciden en que el enriquecimiento de alimentos es la mejor estrategia a largo plazo en la prevención de la deficiencia de hierro. Nuestro objetivo es evaluar el efecto de una mezcla láctea fortificada con hierro y zinc sobre los niveles de hemoglobina en niños de 2 a 10 años. Material y métodos: Se realizó un ensayo clínico aleatorizado, doble ciego, controlado en una comunidad ubicada a 2,590 metros sobre el nivel del mar. Se incluyeron niños con niveles en el límite inferior de los rangos de normalidad o anemia leve. Asignamos a los participantes de manera aleatoria que recibieran la mezcla láctea fortificada con hierro y zinc o una mezcla láctea no fortificada. La mezcla láctea se administró cinco días a la semana durante 24 semanas. Nuestro resultado principal fue el nivel de hemoglobina corregida tomando en cuenta la altura sobre el nivel del mar y los índices antropométricos se evaluaron como resultado secundario. La magnitud de la diferencia observada entre los grupos se estimó mediante la prueba t de Student. Todos los análisis se realizaron por intención de tratar. Resultados: Se asignaron al azar 67 niños, intervención: n=32 y control: n=35. La edad media fue de 5,8 años; 30 eran mujeres. La hemoglobina al final del seguimiento fue 13,1 gr/dL (0,9) en el grupo experimental mientras que, en el grupo control, fue de 12,1 gr/dL (0,8); p <0,001. Asimismo, se evidenció una diferencia positiva en los indicadores antropométricos en el grupo experimental. Conclusión: La mezcla láctea fortificada con hierro y zinc aumenta los niveles de hemoglobina y los índices antropométricos en niños de 2 a 10 años.

Objetive:Previous research agrees tha tfood fortification is the best long-term strategy for preventing iron deficiency. Our goal is to evaluate the effect of a dairy mixture fortified with iron and zinc on hemoglobin levels in children aged 2 to 10 years. Material and methods: A randomized, double-blind, controlled clinical trial was conducted in a community located 2,590 meters above sea level. Children with normal levels of hemoglobin or mild anemia were included. We assign participants to receive the iron-zinc-fortified dairy mixture or an unfortified dairy mixture. The supplement was administered five days a week for 24 weeks. Our main result was the corrected hemoglobin level taking into account the height above sea level and anthropometric indices were evaluated as a secondary result. The magnitude of the difference observed between the groups was estimated by the Student t-test. All analyzes were done with the intention to treat. Results: 67 children were randomly assigned, intervention: n=32 and control: n=35. The mean age was 5.8 years; 30 were women. Hemoglobin at the end of the follow-up was 13.1 g/dL(0.9) in the experimental group, while, in the control group, it was 12.1 g/dL(0.8); p <0.001. Likewise, a positive difference was evidenced in the anthropometric indicators in the experimental group. Conclusion: Dairy mixture fortified with iron and zinc increases hemoglobin levels and anthropometric indices in children from 2 to 10 years old.

Mortality in cutaneous malignant melanoma and its association with Neutrophil-to-Lymphocyte ratio.

INTRODUCTION: Cutaneous malignant melanoma (CMM) incidence has risen rapidly in the last 50 years. Poor progression and high mortality characterize CMM, making a thorough understanding of progression and associated factors essential for optimizing care. AIMS: We assessed the association between the Neutrophil-to-Lymphocyte Ratio (NLR) and mortality in adults with CMM from an entirely mixed-race Hispanic population during 12 consecutive years of extensive follow-up. MATERIAL & METHODS: We performed a retrospective cohort study in a tertiary hospital in Peru. NLR was categorized with a cutoff value higher or equal than 3. We collected demographic variables, laboratory results and treatments at baseline of follow-up. Cox regression analysis was performed, and we calculated crude and adjusted hazard ratios (HR) and their 95% confidence interval (95%CI). RESULTS: The analysis was from 615 CMM cases, and there were 378 deaths. Most melanomas (63.6%) were acral lentiginous. The crude analysis showed that high NLR is a risk factor for mortality, HR = 2.52; 95%CI (2.03-3.14). High NRL ratio remains statistically significant after adjusting for confounding variables, aHR = 1.61; 95%CI (1.16-2.24). Other risk factors for mortality were clinical stages III and IV, older than 60 years, females and greater Breslow thickness. CONCLUSIONS: We concluded that high NRL ratio is a risk factor for mortality and should be monitored in every patient who is diagnosed with malignant melanoma during their first blood count. It should then be carried out in follow-up controls for patients of clinical stage III and IV only, or in patients who present a relapse.

Prevalencia y factores asociados a la intención de vacunarse contra la COVID-19 en el Perú / Prevalence and factors associated with the intention to be vaccinated against COVID-19 in Peru

RESUMEN Objetivos: Estimar la prevalencia y los factores asociados a la intención de vacunación (IDV) contra la COVID-19 en el Perú. Materiales y métodos: Estudio transversal analítico utilizando una encuesta realizada por la Universidad de Maryland, EUA, en Facebook. La variable dependiente fue la IDV. Se calcularon razones de prevalencia (RP) crudas y ajustadas, con sus intervalos de confianza al 95% (IC95%), mediante modelos lineales generalizados de la familia Poisson para evaluar la asociación de variables sociodemográficas, el cumplimiento de estrategias comunitarias de mitigación, los síntomas de la COVID-19, la salud mental y la aceptación de la vacunación ante la recomendación (AVR) por diversos actores y autoridades sanitarias. Resultados: Se analizaron los datos de 17 162 adultos. La prevalencia general de la IDV fue del 74,9%. Se asociaron a una menor prevalencia de la IDV ser de sexo femenino (RP=0,95; IC95%:0,94-0,97), vivir en un pueblo (RP=0,95; IC95%:0,91-0,99) o en una aldea u otra área rural (RP=0,90; IC95%:0,86-0,93) y la AVR de políticos (RP=0,89; IC95%: 0,87-0,92). Contrariamente, tener síntomas de COVID-19 (RP=1,06; IC95%:1,03-1,09), inseguridad económica (RP=1,04; IC95%: 1,01-1,06), miedo a enfermar o que un familiar enferme de COVID-19 (RP=1,49; IC95%: 1,36-1,64) y la AVR de familiares y amigos (RP=1,10; IC95%: 1,08-1,12), trabajadores de la salud (RP=1,29; IC95%: 1,26-1,32), la Organización Mundial de la Salud (RP=1,34; IC95%: 1,29-1,40) y funcionarios del gobierno (RP=1,18; IC95%: 1,15-1,22) se asociaron con mayor prevalencia de IDV. Conclusiones: Tres cuartas partes de los encuestados manifiestan IDV. Existen factores potencialmente modificables que podrían mejorar la aceptación de la vacuna.

ABSTRACT Objectives: To estimate the prevalence and factors associated with the intention to be vaccinated (ITV) against COVID-19 in Peru. Materials and methods: Analytical cross-sectional study using the survey conducted by the University of Maryland, USA, on Facebook. The dependent variable is the ITV. Crude and adjusted prevalence ratios (PR) were calculated, with their 95% confidence intervals (95% CI) using generalized linear models of the Poisson family, in order to evaluate the association of sociodemographic variables, compliance with community mitigation strategies, symptoms of COVID-19, mental health and acceptance of vaccination before the recommendation (AVR) by various actors and health authorities, with the ITV. Results: Data from 17,162 adults were analyzed. The overall prevalence of the ITV was 74.9%. A lower prevalence of the ITV was associated with the female sex (PR=0.95; 95% CI: 0.94-0.97), living in a town (PR=0.95; 95% CI: 0.91-0.99) or village or other rural area (PR=0.90; 95% CI: 0.86-0.93) and the AVR of politicians (PR=0.89; 95% CI: 0.87-0.92). Conversely, having COVID-19 symptoms (PR=1.06; 95% CI: 1.03-1.09), economic insecurity (PR=1.04; 95% CI: 1.01-1.06), fears of becoming seriously ill or that a family member becomes seriously ill from COVID-19 (PR=1.49; 95% CI: 1.36-1.64) and the AVR of family and friends (PR=1.10; 95% CI: 1.08-1.12), healthcare workers (PR=1.29; 95% CI: 1.26-1.32), World Health Organization (PR=1.34; 95% CI: 1.29-1.40) and government officials (PR=1.18; 95% CI: 1.15-1.22) was associated with a higher prevalence of the ITV. Conclusions: Three-quarters of the respondents had the ITV. There are potentially modifiable factors that could improve vaccine acceptance.

Revisiones de alcance, revisiones paraguas y síntesis enfocada en revisión de mapas: aspectos metodológicos y aplicaciones / Scoping reviews, umbrella reviews and focused mapping review synthesis: methodological aspects and applications

RESUMEN Nuestro objetivo fue comentar las diferencias metodológicas y aplicaciones de tres nuevos tipos de revisiones con especial atención a Latinoamérica. Entre estos nuevos tipos de revisiones tenemos a las revisiones de alcance, revisiones paraguas y síntesis enfocada en revisión de mapas. Las revisiones de alcance identifican la naturaleza y extensión de la evidencia, las revisiones paraguas se centran en la síntesis de todas las revisiones sistemáticas que abordan un mismo problema de salud, mientras que las síntesis enfocadas en la revisión de mapas son opciones válidas cuando resulta inviable un mapeo clásico de la evidencia, por abordar demasiados artículos. En la medida de que los investigadores en Latinoamérica se familiaricen con la metodología y utilidad de estos nuevos tipos de revisión, se observará un incremento de la producción científica.

ABSTRACT We aimed to comment on the methodological differences and applications of these three types of reviews with special attention to Latin America. Among these new types of reviews we have the scoping review, umbrella review and focused mapping review synthesis. Scoping reviews identify the nature and extent of the evidence, umbrella reviews focus on the synthesis of all systematic reviews that address the same health problem, while focused mapping review syntheses are valid options when a classical mapping of the evidence is not feasible, due to addressing too many articles. As researchers in Latin America become familiar with the methodology and usefulness of these new types of review, an increase in scientific production will be observed.

Revisiones de alcance, revisiones paraguas y síntesis enfocada en revisión de mapas: aspectos metodológicos y aplicaciones / Scoping reviews, umbrella reviews and focused mapping review synthesis: methodological aspects and applications

RESUMEN Nuestro objetivo fue comentar las diferencias metodológicas y aplicaciones de tres nuevos tipos de revisiones con especial atención a Latinoamérica. Entre estos nuevos tipos de revisiones tenemos a las revisiones de alcance, revisiones paraguas y síntesis enfocada en revisión de mapas. Las revisiones de alcance identifican la naturaleza y extensión de la evidencia, las revisiones paraguas se centran en la síntesis de todas las revisiones sistemáticas que abordan un mismo problema de salud, mientras que las síntesis enfocadas en la revisión de mapas son opciones válidas cuando resulta inviable un mapeo clásico de la evidencia, por abordar demasiados artículos. En la medida de que los investigadores en Latinoamérica se familiaricen con la metodología y utilidad de estos nuevos tipos de revisión, se observará un incremento de la producción científica.

ABSTRACT We aimed to comment on the methodological differences and applications of these three types of reviews with special attention to Latin America. Among these new types of reviews we have the scoping review, umbrella review and focused mapping review synthesis. Scoping reviews identify the nature and extent of the evidence, umbrella reviews focus on the synthesis of all systematic reviews that address the same health problem, while focused mapping review syntheses are valid options when a classical mapping of the evidence is not feasible, due to addressing too many articles. As researchers in Latin America become familiar with the methodology and usefulness of these new types of review, an increase in scientific production will be observed.

Factores asociados a la muerte por COVID-19 en pacientes admitidos en un hospital público en Tacna, Perú

Objetivo: Describir las características demográficas, clínicas, laboratoriales y de tratamiento de pacientes hospitalizados por la COVID-19 y determinar los factores asociados a la mortalidad hospitalaria. Materiales y métodos: Estudio de cohorte retrospectivo de pacientes adultos hospitalizados por la COVID-19. Se extrajeron datos demográficos, clínicos, laboratoriales y de tratamiento de las historias clínicas de pacientes que ingresaron al Hospital III Daniel Alcides Carrión de Tacna. Para el análisis de supervivencia se empleó el modelo de riesgos proporcionales de Cox y se calcularon los cocientes de riesgo instantáneos (HR) crudos y ajustados con sus respectivos intervalos de confianza al 95% (IC 95%). Resultados: Se evaluó a 351 pacientes, el 74,1% eran hombres; las comorbilidades más comunes fueron obesidad (31,6%), hipertensión (27,1%) y diabetes mellitus (24,5%). La mediana de tiempo de hospitalización fue 8 días (RIC: 4-15). El 32,9% falleció durante el seguimiento. El análisis multivariado mostró un aumento del riesgo de morir asociado a la edad ≥65 años, HR = 3,55 (IC 95%: 1,70-7,40); al incremento de lactato deshidrogenasa >720 U/L, HR = 2,08 (IC 95%: 1,34-3,22); y a la saturación de oxígeno por debajo del 90%, principalmente cuando fue menor al 80%, HR = 4,07 (IC 95%: 2,10-7,88). Además, el uso de colchicina en el tratamiento tuvo un efecto protector, HR = 0,46 (IC 95%: 0,23-0,91). Conclusiones: Los factores asociados a muerte por la COVID-19 incluyeron ser mayor de 65 años, tener saturación de oxígeno menor de 90% y elevación del lactato deshidrogenasa >720 U/L; el tratamiento con colchicina podría mejorar el pronóstico de los pacientes.

Objective: To describe the clinical, laboratory and treatment characteristics of COVID-19 patients and to determine the factors associated with mortality during hospital stay. Materials and Methods: Retrospective cohort study of adult COVID-19 inpatients. The clinical, laboratory and treatment data were obtained from the medical records of patients from the Hospital Nivel III Daniel Alcides Carrión in Tacna. For the survival analysis we used the Cox proportional hazards model, and we calculated crude and adjusted hazard ratios (HR) with 95% confidence intervals (95% CI). Results: We evaluated 351 patients; 74.1% of them were men. The most common comorbidities were obesity (31.6%), hypertension (27.1%) and diabetes mellitus (24.5%). The median time of hospitalization was 8 days (IQR: 4-15). From the total of patients, 32.9% died during follow-up. The multivariate analysis showed an increased risk of dying associated with the following: age ≥65 years, HR = 3.55 (95% CI: 1.70-7.40); increase in lactate dehydrogenase >720 U/L, HR = 2.08 (95% CI: 1.34-3.22); and oxygen saturation less than 90%, mainly when it was less than 80%, HR = 4.07 (95% CI: 2.10-7.88). In addition, the use of colchicine during treatment showed a protective effect, HR = 0.46 (95% CI: 0.23-0.91). Conclusions: Risk factors for mortality due to COVID-19 included being older than 65 years, having oxygen saturation less than 90%, and elevated lactate dehydrogenase >720 U/L; colchicine treatment could improve the prognosis of patients.

Association between knowledge about cervical cancer and having a Papanicolaou test in peruvian women. / Asociación entre conocimientos acerca del cáncer de cuello uterino y realizarse una prueba de Papanicolaou en mujeres peruanas.

OBJETIVES: To estimate the association between having knowledge about cervical cancer (CC) and having a Pap test (PAP) in Peruvian women over 30 years old. MATERIALS AND METHODS: A secondary analysis of the Demographic and Family Health Survey of the years 2015 to 2017 was carried out. The level of knowledge was evaluated using the questions, do you think that cancer can be prevented?, Have you ever heard of CC?, Have you ever heard of human papillomavirus (HPV)? And do you think HPV can cause CC? The dependent variable was the realization of a PAP in the last two years. To estimate the association, generalized linear models of the raw and adjusted Poisson family were used. The measure of association was the adjusted prevalence ratio (aPR) with its respective 95% confidence intervals (95% CI). RESULTS: Data from 21 563 women were analyzed. The prevalence of having performed a PAP in the last two years was 52.4%. It was found that, those who responded that cancer can be prevented (aPR = 1.09; 95% CI: 1.01-1.17), who had heard of CC (aPR = 1.27; 95% CI: 1.14-1 , 40) or HPV (aPR = 1.20; 95% CI: 1.13-1.28) or who responded that HPV could cause CC (aPR = 1.21; 95% CI: 1.11-1.33) had a higher prevalence of having performed a PAP in the last two years. CONCLUSIONS: Having knowledge about CC and HPV has been associated with having performed a PAP in the last two years.

OBJETIVOS: Estimar la asociación entre tener conocimientos acerca del cáncer de cuello uterino (CaCu) y re alizarse una prueba de Papanicolaou (PAP) en mujeres peruanas mayores de 30 años. MATERIALES Y MÉTODOS: Se realizó un análisis secundario de la Encuesta Demográfica y de Salud Familiar de los años 2015 al 2017. El nivel conocimiento fue evaluado utilizando las preguntas: ¿considera usted que el cáncer se puede prevenir?, ¿alguna vez ha oído hablar del CaCu?, ¿alguna vez ha oído hablar del virus del papiloma humano (VPH)? y ¿considera que el VPH puede causar CaCu? La variable dependiente fue la realización de un PAP en los dos últimos años. Para estimar la asociación se utilizaron modelos lineales generalizados de la familia Poisson crudos y ajustados. La medida de asociación fue la razón de prevalencia ajustada (RPa) con sus respectivos intervalos de confianza al 95% (IC 95%). RESULTADOS: Se analizaron datos de 21 563 mujeres. La prevalencia de haberse realizado un PAP en los últimos dos años fue 52,4%. Se encontró que, quienes respondieron que se puede prevenir el cáncer (RPa = 1,09; IC 95%: 1,01-1,17), que habían oído hablar del CaCu (RPa = 1,27; IC 95%: 1,14-1,40) o del VPH (RPa = 1,20; IC 95%:1,13-1,28) o que respondieron que el VPH podía causar CaCu (RPa = 1,21; IC 95%: 1,11 1,33) tuvieron una mayor prevalencia de haberse realizado un PAP en los últimos dos años. Conclusiones: Tener conocimientos sobre CaCu y VPH se asoció con haberse realizado un PAP en los últimos dos años.

Asociación entre conocimientos acerca del cáncer de cuello uterino y realizarse una prueba de Papanicolaou en mujeres peruanas / Association between knowledge about cervical cancer and having a Papanicolaou test in peruvian women

Resumen Objetivos: Estimar la asociación entre tener conocimientos acerca del cáncer de cuello uterino (CaCu) y re alizarse una prueba de Papanicolaou (PAP) en mujeres peruanas mayores de 30 años. Materiales y métodos: Se realizó un análisis secundario de la Encuesta Demográfica y de Salud Familiar de los años 2015 al 2017. El nivel conocimiento fue evaluado utilizando las preguntas: ¿considera usted que el cáncer se puede prevenir?, ¿alguna vez ha oído hablar del CaCu?, ¿alguna vez ha oído hablar del virus del papiloma humano (VPH)? y ¿considera que el VPH puede causar CaCu? La variable dependiente fue la realización de un PAP en los dos últimos años. Para estimar la asociación se utilizaron modelos lineales generalizados de la familia Poisson crudos y ajustados. La medida de asociación fue la razón de prevalencia ajustada (RPa) con sus respectivos intervalos de confianza al 95% (IC 95%). Resultados: Se analizaron datos de 21 563 mujeres. La prevalencia de haberse realizado un PAP en los últimos dos años fue 52,4%. Se encontró que, quienes respondieron que se puede prevenir el cáncer (RPa = 1,09; IC 95%: 1,01-1,17), que habían oído hablar del CaCu (RPa = 1,27; IC 95%: 1,14-1,40) o del VPH (RPa = 1,20; IC 95%:1,13-1,28) o que respondieron que el VPH podía causar CaCu (RPa = 1,21; IC 95%: 1,11 1,33) tuvieron una mayor prevalencia de haberse realizado un PAP en los últimos dos años. Conclusiones: Tener conocimientos sobre CaCu y VPH se asoció con haberse realizado un PAP en los últimos dos años.

Abstract Objetives: To estimate the association between having knowledge about cervical cancer (CC) and having a Pap test (PAP) in Peruvian women over 30 years old. Materials and Methods: A secondary analysis of the Demographic and Family Health Survey of the years 2015 to 2017 was carried out. The level of knowledge was evaluated using the questions, do you think that cancer can be prevented?, Have you ever heard of CC?, Have you ever heard of human papillomavirus (HPV)? And do you think HPV can cause CC? The dependent variable was the realization of a PAP in the last two years. To estimate the association, generalized linear models of the raw and adjusted Poisson family were used. The measure of association was the adjusted prevalence ratio (aPR) with its respective 95% confidence intervals (95% CI). Results: Data from 21 563 women were analyzed. The prevalence of having performed a PAP in the last two years was 52.4%. It was found that, those who responded that cancer can be prevented (aPR = 1.09; 95% CI: 1.01-1.17), who had heard of CC (aPR = 1.27; 95% CI: 1.14-1 , 40) or HPV (aPR = 1.20; 95% CI: 1.13-1.28) or who responded that HPV could cause CC (aPR = 1.21; 95% CI: 1.11-1.33) had a higher prevalence of having performed a PAP in the last two years. Conclusions: Having knowledge about CC and HPV has been associated with having performed a PAP in the last two years.

Myeloid sarcoma of the tongue as a first manifestation of acute promyelocytic leukemia: A case report.

INTRODUCTION: We describe a 35-year-old male patient showing a myeloid sarcoma (MS) of the tongue as the first manifestation of acute promyelocytic leukemia (APL). The MS can appear in all parts of the human body, but it is extremely rare in the tongue. CLINICAL CASE: The main symptoms were a pain in the tongue, asthenia, gingivorrhagia, fever. We found a tumor in the tongue, which was irregular in size and located in the posterior region of the right lateral edge of the tongue. The diagnosis of MS was made by the anatomopathological and immunohistochemical study, while the definite diagnosis of APL was confirmed by the molecular test. The treatment of APL was based on the administration of trans-retinoic acid 45 mg/m2 daily continuously and daunorubicin 60 mg/m2 every other day for 4 doses, with a favorable therapeutic response to APL and MS. CONCLUSION: Promyelocytic myeloid cells can infiltrate many organs extramedullary, such as the tongue, and this might precede bone marrow infiltration. The early identification of myeloid sarcoma allows to carry out an early treatment of the APL.